1. Schafer E, Ewe K. Treating irritable bowel syndrome. Advances Med. 1990;108(25):42-50.
2. Panadol Woman Product Packaging. GlaxoSmithKline, 2019.
3. De los Santos AR, Smijanovich R, Perez MS, Marti ML, Di Girolamo G. Antispasmodic/analgesic associations in primary dysmenorrhea double-blind crossover placebo-controlled clinical trial. Int J Clin Pharm Res. 2001;XXI(1):21-29.
4. Rathod R, Misra D. SPICE: an Indian experience with Buscopan plus in spasm and pain. IJCP 2008;19(4):21-26.
5. Jozwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm 2014;71(1):11-23.
6. Prescott LF. Paracetamol: Past, present, and future. Am J Ther. 2000 Mar;7(2):143-7.
7. Tytgat GN. Hyoscine butylbromide: A review of its use in the treatment of abdominal cramping and pain. Drugs. 2007;67(9):1343-57.
8. Mueller-Lissner S, et al. Placebo- and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain. Ailment Pharmacol Ther. 2006;23:1741-1748.
9. U.S. Food and Drug Administration (FDA). Medication guide for non-steroidal anti-inflammatory drugs (NSAIDs). U.S. FDA. 2007 Aug. Accessed 17 May 2019.
By clicking the link(s) above, you will be taken to an external website that is independently operated and not managed by GSK. GSK assumes no responsibility for the content on the website. If you do not wish to leave this website, do not click on the links above.